Information Provided By: 
Fly News Breaks for September 6, 2018
SRPT
Sep 6, 2018 | 08:25 EDT
Credit Suisse analyst Martin Auster started Sarepta with an Outperform rating and $178 price target. Despite high expectations for the DMD gene therapy program, the analyst sees room for continued share appreciation as the program develops. While he expects initial data from all three clinical stage gene therapy programs likely will demonstrate robust dystrophin expression in skeletal muscle, Auster thinks Sarepta's first mover advantage and strong initial data sets a high bar and a strong competitive position.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
